Isosorbide Mononitrate Indications
Isosorbide mononitrate is NOT recommended as guideline-directed therapy for heart failure, and its primary indication is for prevention of angina pectoris in chronic coronary artery disease. 1
Primary Indication: Chronic Stable Angina
Isosorbide mononitrate is FDA-approved for the prevention of angina pectoris due to coronary artery disease. 1 However, it is critical to understand that it cannot abort acute angina episodes due to insufficient rapidity of onset. 1
Dosing for Angina Prevention
- Starting dose: 20 mg three times daily 2, 3
- Target dose: 40 mg three times daily 2, 3
- Extended-release formulation: 30-240 mg once daily, taken early morning 1
The extended-release formulation provides at least 12 hours of antianginal activity when administered once daily in the morning. 1
Important Contraindication in Heart Failure
Isosorbide mononitrate is explicitly NOT recommended by ACC/AHA/HFSA guidelines for heart failure with reduced ejection fraction (HFrEF). 4 This is a critical distinction that clinicians must understand.
Why Isosorbide Dinitrate (Not Mononitrate) for Heart Failure
When nitrate therapy is indicated for HFrEF, only isosorbide dinitrate (in combination with hydralazine) is guideline-recommended, particularly for self-identified Black patients. 5, 6
- Isosorbide dinitrate + hydralazine combination shows a 43% relative risk reduction in all-cause mortality 5, 6
- Starting dose: 20 mg isosorbide dinitrate + 37.5 mg hydralazine three times daily 5, 6
- Target dose: 40 mg isosorbide dinitrate + 75 mg hydralazine three times daily 5, 6
The evidence supporting this combination is robust, with an NNT of 21 to prevent one death over 12 months. 6
Acute Coronary Syndromes: Limited Role
In unstable angina/NSTEMI, intravenous nitroglycerin (not oral isosorbide mononitrate) is the preferred nitrate formulation for patients with ongoing ischemic symptoms unrelieved by sublingual nitroglycerin. 2, 3
- Oral isosorbide mononitrate may be used as maintenance therapy: 20 mg twice daily with 12-24 hour duration of effect 2, 3
- However, IV nitroglycerin remains first-line for acute management 2, 3
Vasospastic Angina: Second-Line Therapy
For vasospastic angina (coronary artery spasm), calcium channel blockers are first-line therapy, with long-acting nitrates like isosorbide mononitrate as second-line agents. 7
- First-line: Calcium channel blocker (e.g., verapamil 40 mg BID, uptitrated) 7
- Second-line: Add isosorbide mononitrate 10 mg BID 7
- Always provide sublingual nitroglycerin for acute episodes 7
Critical Safety Considerations
Absolute Contraindications
- Concurrent phosphodiesterase-5 inhibitor use: Contraindicated within 24 hours of sildenafil or 48 hours of tadalafil due to risk of profound hypotension, MI, and death 2, 3
- Hypotension: Avoid if systolic BP <90 mmHg or >30 mmHg below baseline 2, 3
- Severe bradycardia or tachycardia 2, 3
Tolerance Development
Tolerance to antianginal effects develops with continuous exposure. 1 Extended-release formulations at 30-60 mg doses lost efficacy by day 42 in clinical trials, though 120-240 mg doses maintained some benefit. 1 This underscores the importance of nitrate-free intervals with immediate-release formulations.
Elderly Patients
Use with extreme caution in elderly patients due to increased risk of severe orthostatic hypotension, particularly if volume-depleted or on multiple medications. 1 Elderly patients have reduced baroreceptor function and may develop paradoxical bradycardia with increased angina. 1
Evidence Against Use in HFpEF
In heart failure with preserved ejection fraction (HFpEF), isosorbide mononitrate actually decreased daily activity levels and did not improve quality of life or exercise capacity compared to placebo. 8 Patients receiving 120 mg daily had significantly fewer hours of activity per day (-0.30 hours, p=0.02) and a trend toward lower overall activity. 8